ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will host and webcast a Research & Development (R&D) Day on Wednesday, October 18, 2023.
During the event, members of Supernus' senior management team will provide an overview of the Company's pipeline, with emphasis on SPN-820/821, SPN-817 and new clinical candidates from the Supernus's discovery program. In addition, a key opinion leader will share his perspectives on the current treatment paradigms, unmet medical needs and the Company's clinical development programs.
Presentation Date: Wednesday, October 18, 2023
Time: 8:00 a.m. ET (registration); 8:30 a.m. to approx. 12:00 p.m. ET (presentation)
Location: Convene at 530 Fifth Avenue (btw 44th-45th St.), New York, NY 10036
Registration and webcast information can be found here: https://events.convene.com/supernus-rnd-day-2023 and also on the Events & Presentations section in the Investor Relations section on the Company's website at www.supernus.com. Webcast participants may submit questions via email at Brandon.Weiner@westwicke.com. Questions must be received by October 16, 2023 to be addressed during the live event. Presentation materials and a live webcast will be accessible in the Events & Presentations section in the Investor Relations section ...